| P/E (FY) | — | Sales (TTM) | $79.2M |
| Earnings (TTM) | -$144.0M | ROE | −14.47% |
| Net Margin | −194.88% | ROIC | −19.73% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −46.31% |
| Market Cap | $1.62B | Trading Days | 1408 |
| 52W High | 8.44 |
| 52W Low | 2.75 |
| % Off High | −37.32% |
| YTD | 54.68% | 1Y | 7.52% |
| 3Y | −31.21% | 5Y | −67.10% |
| Since incept. (ann.) | −34.84% |
CA 85% · US 15%
| Ann. Volatility (1Y) | 75.97% | Ann. Volatility (3Y) | 68.84% |
| Sharpe (1Y) | 0.47 | Sharpe (3Y) | 0.17 |
| Max Drawdown (1Y) | −54.94% | Max Drawdown (3Y) | −75.03% |
| Beta (3Y, vs SPY) | 2.46 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| INVA | Innoviva, Inc. | $1.61B | 6.6 |
| SRPT | Sarepta Therapeutics, Inc. | $1.63B | — |
| SLN | Silence Therapeutics plc | $1.64B | — |
| ZYME | Zymeworks Inc. | $1.65B | — |
| GENB | Generate Biomedicines, Inc. | $1.68B | — |
| BHC | Bausch Health Companies Inc. | $1.69B | 10.8 |
| SEPN | Septerna, Inc. | $1.53B | — |
| ANAB | ANAPTYSBIO, INC | $1.52B | — |
| SNDX | Syndax Pharmaceuticals Inc | $1.74B | — |
| XNCR | Xencor Inc | $1.48B | — |
| PAHC | PHIBRO ANIMAL HEALTH CORP | $1.48B | 30.6 |
| BCAX |
| Bicara Therapeutics Inc. |
| $1.77B |
| — |
